Because SEC23A has been validated as a miR-375 target in a human prostatic carcinoma cell line [33], we further validated SEC23A expression at the protein level in MTC by immunoblotting and immunohistochemistry. The gene discussed is SEC23A; the disease is prostate carcinoma.